VAP-A Antibody (604101) [Alexa Fluor® 350]

• Reactivity: Hu
• Applications: WB, IHC
• Clone: 604101
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 350

VAP-A Antibody (604101) [Alexa Fluor® 350] Summary

• Immunogen: E. coli-derived recombinant human VAP-A
  Ala2-Met132
  Accession # Q9P0L0
• Specificity: Detects human VAP‑A in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant human VAP-B or recombinant rat VAP-B is observed.
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for VAP-A Antibody (604101) [Alexa Fluor® 350]

• hVAP-33
• MGC3745,33 kDa VAMP-associated protein
• VAMP (vesicle-associated membrane protein)-associated protein A, 33kDa
• VAMP-A
• VAP-33
• VAP33VAMP (vesicle-associated membrane protein)-associated protein A (33kD)
• VAPA
• VAP-A
• VAP-AVAMP-associated protein A
• vesicle-associated membrane protein-associated protein A

Background

Vesicle-associated membrane protein (VAMP)-associated protein A (VAP-A; also VAMP-A and VAP-33) is a 33 kDa, ubiquitously expressed, type IV transmembrane protein belonging to the VAP family of proteins (1). It is found in plasma and ER membranes as well as in intracellular vesicles as a homodimer and a heterodimer with VAP-B. Human VAP-A is synthesized as a 249 amino acid (aa) precursor that contains a 227 aa cytoplasmic domain and a 21 aa transmembrane region. The cytoplasmic domain contains a mobile sperm protein (MSP) domain (aa 13-131) and a coiled-coil region (aa 169-205). Human VAP-A is 97% aa identical to mouse and rat VAP-A. VAP-A and VAP-B recruit FFAT (two phenylalanines in an acidic tract)-motif-containing proteins to the cytosolic surface of ER membranes through a conserved region within their MSP domain, and they have been implicated in regulation of membrane transport, phospholipid biosynthesis, and the unfolded protein response (2, 3). Their ability to interact with lipid-transfer/binding proteins (LT/BPs) may affect the lipid composition of certain cellular membranes (2, 4). VAPs play a critical role in maintaining the structural and functional properties of the Golgi complex (2). Knockdown of VAP reduces the levels of phosphatidylinositol‑4‑phosphate (PI4P), diacylglycerol (DAG), and sphingomyelin (SM) in Golgi membranes and exports pleiotropic effects in Golgi-mediated transport (2). The effects of VAPs are mediated by their interacting FFAT-motif-containing proteins Nir2, OSBP, and CERT (2). VAPs provide a scaffold for these LT/BPs at the ER-Golgi membrane contact sites, thereby affecting the lipid composition of the Golgi membranes and consequently their structural and functional identities (2). VAP-A associates with and regulates the neurite outgrowth-promoting activity of protrudin, a protein that promotes neurite formation (5).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.